Beacon Biosignals
PrivateLast Round
Series B
Apr 6, 2026
Est. Valuation
$286.85M
Total Funding Raised
$224M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Beacon Biosignals operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in April 2026.
Beacon Biosignals is a healthcare technology company that provides an artificial intelligence-driven EEG analysis and diagnosis platform to accelerate drug development and improve brain health outcomes.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Medical AI, Medical Devices, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting, Hardware Sales, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beacon Biosignals Comparables
Compare Beacon Biosignals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cumulus Neuroscience | 77% | |
| Zeto, Inc. | 77% | |
| Empatica | 76% |
For institutional investors. Book with your work email.
Beacon Biosignals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Apr 6, 2026 | ||||
| Series B | Nov 13, 2025 | ||||
| Series A | Nov 8, 2021 | ||||
| Seed | May 30, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Beacon Biosignals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| S32 | Series B |
| Kicker Ventures | Series B |
| GV | Series B |
| JSL Health Capital | Series B |
| Nexus NeuroTech Ventures | Series B |
| Innoviva | Series B |
| Catalio Capital Management | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 1, 2026
Grew 38% QoQ, from 121 to 167 employees.
- May 14, 2026
Secured a multi-year deal with a major biopharma company.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- acquiresOct 22, 2026
On Oct 22nd '26 in Massachusetts, Beacon acquires Snap Diagnostics, LLC, a home sleep testing provider serving patients in all 50 states, more than doubling its patient reach and creating a national channel for EEG-enabled home sleep testing starting in 2027.
- partners_withOct 21, 2026
On Oct 19th '26 in Massachusetts, Beacon partners with Project Sleep to connect AI-driven neurotechnology with a national patient, advocate, and researcher community and reach people with idiopathic hypersomnia and narcolepsy earlier in their diagnostic journeys.
- attends_eventOct 19, 2026
Beacon plans to participate in Project Sleep's 7th annual Sleep Advocacy Forum on Oct 26th '26, in District of Columbia, as part of its joint work with Project Sleep.
For institutional investors. Book with your work email.
Beacon Biosignals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Beacon Biosignals's valuation, stock price, and market status.
Is Beacon Biosignals a public or private company?
Beacon Biosignals is a private company.
What is the current stock price of Beacon Biosignals?
Beacon Biosignals is a private company, so its shares have no public market price. Caplight tracks Beacon Biosignals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beacon Biosignals worth (valuation)?
Beacon Biosignals's valuation is estimated at $286.9M based on funding round data.
Can I buy Beacon Biosignals stock?
Beacon Biosignals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beacon Biosignals's last funding round?
Beacon Biosignals's most recent funding round was Series B on April 6, 2026.
Who are the main investors in Beacon Biosignals?
Key investors in Beacon Biosignals include GV, Innoviva, General Catalyst.
Will Beacon Biosignals IPO soon?
No public IPO plans have been announced for Beacon Biosignals.
How can I track Beacon Biosignals secondary market activity?
Caplight tracks bids, offers, and trades in Beacon Biosignals's shares on secondary markets.